Jerusalem-based Teva Pharmaceuticals announced this week the U.S. launch of its ProAir Digihaler.
The sensor-laden albuterol dispenser requires a prescription, and is indicated for those aged four years or older with reversible obstructive airway diseases such as asthma and COPD, as well as for the prevention of exercise-induced bronchospasm (EIB) among this same group.
The device connects to a...
Digital respiratory health company Propeller Health has received 510(k) clearance for a sensor and app intended for use with AstraZeneca's Symbicort inhaler for asthma and COPD, the company announced today.
The tool – which, according to the agency, was submitted to the agency in September and greenlit in late March – was developed in a previously unannounced partnership with the Cambridge,...
Innovation and tech company Satellite Applications Catapult and the NHS Arden and Greater East Midlands Commissioning Support Unit (CSU) announced this week that they have agreed a formal partnership that looks at leveraging the potential of satellite technology in the digital transformation of healthcare.
Oxfordshire-based Satellite Applications Catapult, which was established by Innovate UK in...
The Loop System, a continuous remote monitor developed by Palo Alto-based startup Spry Health, received 510(k) clearance from the FDA last Friday, according to an update to the agency’s database that was confirmed by the company.
Designed for management of COPD and other chronic conditions, the wristband wearable collects and monitors a user’s pulse-oximetry, respiration, heart rate and blood...
At MEDinIsrael 2019 this week, a conference in Tel Aviv sponsored by the Israeli Export Institute, Dr. Lena Granovsky, director of analytics and big data at Teva Pharmaceuticals, spoke on and off stage about the work the top Israeli pharma company has been doing in digital health. These topics included the company's recently FDA-cleared smart inhaler ProAir Digihaler, as well as more broad...
Digital therapeutics company Kaia Health has unveiled a feasibility study to examine the impact of its digital therapeutic treatment of Chronic Obstructive Pulmonary Disease (COPD) on Japan’s ageing population. This follows a German pilot study which successfully decreased symptoms.
COPD is an umbrella term to describe chronic lung diseases that cause limitations in lung airflow. According to the...
While recent news of international product launches and recent M&As might suggest a cutthroat market, new data released this week by Research2Guidance suggest that there is still plenty of room in the digital respiratory health sector for both existing and new market players.
According to “The Global Digital Respiratory Solutions Market 2009-2023” report, roughly 210 million asthma and COPD...
Respiratory health company Propeller Health, which was recently acquired by ResMed for $225 million, announced this week in San Francisco a partnership with Walgreens and a new feature for users of its platform.
The new feature, called My Pharmacy, will allow Propeller’s end users, patients with asthma and COPD, to connect to pharmacy services without leaving the Propeller app. At launch, users...
Jerusalem-based Teva Pharmaceuticals’ sensor-packed, app-connected digital inhaler has recently received marketing approval from the US FDA, according to a release from the company. The device will first become available next year through a “small number” of healthcare system pilot partnerships, with a full national launch currently planned for 2020.
Teva’s ProAir Digihaler is indicated for the...
Today, Madison, Wisconsin-based digital respiratory health company Propeller Health announced a $20 million funding round led by a $10 million investment from Aptar Pharma. Existing investors Safeguard Scientifics, Social Capital, Hikma Ventures, 3M Ventures, and SR One comprised the other half of the round.
According to a release, the new funding will be invested into the company’s digital...
